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Metzincins are key molecules in the degradation of the extracellular matrix and play an 
important role in cellular processes such as cell migration, adhesion, and cell fusion of 
malignant tumors, including cutaneous melanoma (CM). We hypothesized that genetic variants 
of the metzincin metallopeptidase family genes would be associated with CM-specific survival 
(CMSS). To test this hypothesis, we first performed Cox proportional hazards regression 
analysis to evaluate the associations between genetic variants of 75 metzincin metallopeptidase 
family genes and CMSS using the dataset from the genome-wide association study (GWAS) 
from The University of Texas MD Anderson cancer Center (MDACC) which included 858 non-
Hispanic white patients with CM, and then validated in the dataset from the Harvard GWAS 
study which had 409 non-Hispanic white patients with invasive CM. Four independent SNPs 
(MMP16 rs10090371 C>A, ADAMTS3 rs788935 T>C, TLL2 rs10882807 T>C and MMP9 
rs3918251 A>G) were identified as predictors of CMSS, with a variant-allele attributed hazards 
ratio (HR) of 1.73 (1.32-2.29, 9.68E-05), 1.46 (1.15-1.85, 0.002), 1.68 (1.31-2.14, 3.32E-05) and 
0.67 (0.51-0.87, 0.003), respectively, in the meta-analysis of these two GWAS studies. 
Combined analysis of risk genotypes of these four SNPs revealed a decreased CMSS in a 
dose-response manner as the number of risk genotypes increased (Ptrend < 0.001). An 
improvement was observed in the prediction model [area under the curve (AUC) = 81.4% to 
78.6%], when these risk genotypes were added to the model containing non-genotyping 
variables. Our findings suggest that these genetic variants may be promising prognostic 
biomarkers for CMSS. This article is protected by copyright. All rights reserved 
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Cutaneous melanoma (CM) is the fifth most common cancer in the United States, and its incidence 
rate is increasing by 3% annually [1]. Early diagnosis, immunomodulation (e.g., anti-CTLA4) and targeted 
therapy (e.g., BRAF and MEK inhibitors) have made breakthrough improvements in prognosis of 
advanced-stage CM patients [2,3]. The five-year (2006-2012) survival rate of CM is estimated to be about 
91.5% based on data from the Surveillance, Epidemiology, and End Results (SEER) program.  
CM is a complex disease that originates from melanocytes primarily found in the skin, risk of 
developing melanoma is influenced by both environmental and host factors. For example, ultraviolet (UV) 
exposure, an important environmental factor, has been recognized as an independent risk factor for CM 
[4], which not only increases CM risk but also leads to tumor progression by affecting molecular signaling 
pathways and inhibiting immune reactions [4]. Host factors such as color of the skin, hair, and eyes, as 
well as genetic variants, have also been identified to be involved in CM development and progression [4]. 
In distinction to somatic mutations, germline variants with a low penetrance have a high frequency in the 
general population. In recent years, large-scale genome-wide association studies (GWASs) have 
identified a number of genetic variants as risk factors of many complex diseases, including CM [5]. 
Several single-nucleotide polymorphisms (SNPs) (such as rs7526389, rs1539188, rs1049481 and 
rs2974755) have been found to be independent predictors of CM prognosis [6]. However, GWASs may 
have identified many of the most statistically significant SNPs but also may have missed biologically 
functional and mechanistically important genetic variants that do not rank among the top SNPs. Recently, 
hypothesis-driven and pathway-based (or gene set-based) approaches have been effectively used to 
search for novel functional genetic variants that are associated with risk and prognosis of CM [7]. For 
example, PIWIL4 rs7933369 and rs508485 and DCP1A rs11551405 in the PIWI-piRNA pathway [8] and 
VDBP rs12512631 and RXRA rs7850212 in the vitamin D pathway [9] were found to be associated with 
CM prognosis. Investigations of functional genes and SNPs have provided additional evidence for the 
biological mechanisms underlying observed associations with CM prognosis [10-12]. 
Metzincin metallopeptidase family members, including matrixins, adamlysins, astacins, and 
pappalysins, are calcium-dependent zinc-containing endopepdidases that have proteolytic activities and 
play an important role in degradation of the extracellular matrix and some protein complexes. It has been 
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reported that metzincin family genes play an important role in several cancer-progression-related 
processes, including cell migration, adhesion, and cell fusion of malignant diseases [13-17]. For example, 
matrix metalloproteinase 9 (MMP9) has been reported to be associated with cancer invasiveness and 
metastasis, and inhibitors against MMP9 represent a promising strategy for anti-melanoma therapy [18]. 
MMP12 expression has been reported to be increased in CM and related to tumor invasion and 
metastasis [19]. Moreover, high expression of the disintegrin and metalloproteinase domain-containing 
protein 10 (ADAM10) was found to be related to melanoma metastasis [20]. The disintegrin-
metalloproteinases with thrombospondin domains (ADAMTS) genes have been suggested to act as 
tumor suppressors in various cancers, including melanoma, and ADAMTS18 mutations can promote cell 
growth, migration, and metastasis of melanoma [21]. In addition, other metzincin family members, 
including astacins and pappalysins, have also been reported to be associated with tumorigenesis [22,23].  
To date, there are no reported studies using large-scale GWAS datasets to investigate the role of 
genetic variants of genes in the metzincin metallopeptidase family in melanoma survival. We hypothesize 
that genetic variants of the metzincin metallopeptidase family genes would be associated with CM-
specific survival (CMSS). 
 
MATERIALS AND METHODS  
Study populations 
The discovery dataset included 858 non-Hispanic white patients with CM from a previously 
published GWAS study at The University of Texas MD Anderson Cancer Center (MDACC), who were 
recruited between March 1993 and August 2008 [24]. The GWAS database of genotypes and 
phenotypes, including patient age, sex, primary tumor Breslow thickness, metastasis, ulceration, mitotic 
rate and survival outcome, were available at the dbGaP (accession: phs000187.v1.p1) [25]. In this study, 
genomic DNA extracted from the blood samples was genotyped with Illumina HumanOmni-Quad_v1_0_B 
array. Genome-wide imputation (imputation quality r2 ≥ 0.8) was conducted with the MACH software 
based on the 1000 Genomes CEU population (March 2010 release) [26].  
The replication dataset included 409 non-Hispanic white patients with invasive CM in the two 
cohorts of Nurses’ Health Study (NHS) and Health Professionals Follow-up Study (HPFS) from Harvard 
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University, from which the information of age, sex, survival outcome and genotype data were available. 
Genotyping was performed using the Illumina HumanHap610 array. Genome-wide imputation (imputation 
quality r2 ≥ 0.8) was also performed using the MACH software based on the 1000 Genomes Project CEU 
population (March 2012 release) [27,28]. 
All individuals in the two datasets participated in these studies after providing a written informed 
consent under an Institutional Review Board-approved protocol. 
 
Gene and SNP extraction 
The metzincin metallopeptidase family genes were selected from the HUGO gene family website 
(http://www.genenames.org/cgi-bin/genefamilies/set/901). Genotyped and imputed SNPs of the metzincin 
metallopeptidase family genes were selected to be analyzed with the following quality control criteria: (1) 
a genotyping rate ≥ 95%, (2) a minor allelic frequency (MAF) ≥ 0.05, and (3) Hardy-Weinberg equilibrium 
(HWE) P value ≥ 1×10-5. 
 
Statistical analysis 
CMSS was considered the major end-point in in the present study, which was defined as the date 
from the diagnosis of malignant CM to the time of CM-related death or the time of the last follow-up. In the 
MDACC dataset, Cox proportional hazards regression analysis was performed with adjustment for age, 
sex, Breslow thickness, metastasis, ulceration and mitotic rate (in an additive genetic model). We 
estimated the associations between SNPs in the metzincin metallopeptidase family genes and CMSS by 
calculating hazards ratio (HR) and its 95% confidence interval (CI) using the GenABEL package of R 
software. In the Harvard dataset, only age and sex were available for adjustment in the further Cox 
regression analysis. The false-positive report probability (FPRP) method with a cut-off value of 0.20 was 
used for multiple testing corrections [29]. FPRP was chosen because many imputed SNPs were in 
linkage disequilibrium (LD) among all the SNPs under investigation, and also it is calculated based on 
three factors, including the observed P value, the prior probability of a true association of the tested 
genetic variant with a disease, and the statistical power of the test. In the present study, we assigned a 
prior probability of 0.10 to detect an HR of 2.0 for an association with variant genotypes or minor alleles of 
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the SNPs with P ≤ 0.05. Then, we performed the multivariable stepwise Cox regression analysis including 
clinical variables and validated SNPs to select the independent representative SNPs in the MDACC 
dataset, and a meta-analysis was followed to combine the results between the MDACC and Harvard 
studies using PLINK 1.07. A fixed-effects model was used when no heterogeneity was found between two 
studies (Q-test P-value > 0.10 and I2 < 50.0%); otherwise, a random-effects model was applied. Kaplan-
Meier curve and log-rank test were used to estimate the effects of risk genotypes on the cumulative 
probability of CMSS. Furthermore, we summarized and combined the risk genotypes to assess 
associations between the number of risk genotypes and CMSS. The heterogeneity test of associations 
between subgroups of each clinical variable was conducted by using the Chi-square-based Q-test in 
stratified analyses, and P < 0.05 was considered significant for differences between the subgroups of 
each clinical variable. A time-dependent receiver operating characteristic (ROC) analysis was performed 
to calculate area under curve (AUC) of SNPs and clinical variables by using "survAUC" package of R 
software in the MDACC dataset [30]. In addition, Haploview v4.2 [31] was used to construct a Manhattan 
plot, and LocusZoom [32] was used to produce regional association plots. All statistical analyses were 
performed with SAS software (version 9.4; SAS Institute, Cary, NC, USA), if not specified otherwise. 
 
RESULTS 
Gene and SNP extraction 
Seventy-eight metzincin metallopeptidase family genes were selected from the HUGO 
gene family website (http://www.genenames.org/cgi-bin/genefamilies/set/901) (Supplementary 
Table 1). Three pseudogenes (ADAM1B, ADAM24P and ADAM3B) were excluded from the 
gene list. After quality checks, 13,850 SNPs of 75 genes (i.e., 2,145 genotyped and 11,705 
imputed SNPs) were extracted from the imputed MDACC GWAS dataset for further survival 
analysis. 
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Associations between SNPs in the metzincin metallopeptidase family genes and CMSS in 
the MDACC dataset 
We present the workflow of the analyses in Figure 1. The basic characteristics of the 
MDACC and Harvard studies were described previously [24,33] (Supplementary Table 2). We 
first performed Cox regression analysis with adjustment for age, sex, Breslow’s thickness, 
metastasis, ulceration and mitotic rate to evaluate associations between 13,850 SNPs of the 
metzincin metallopeptidase family genes and CMSS in single locus analysis. Among these 
SNPs, 570 SNPs were significantly associated with CMSS at P ≤ 0.05 in an additive genetic 
model. We then conducted multiple testing corrections for these 570 SNPs, and 322 SNPs with 
FPRP ≤ 0.20 were selected for validation in another independent dataset of the Harvard study 
(Supplementary Figure 1).        
 
Replication of the significant SNPs in the Harvard dataset 
We validated the 322 SNPs by using the Harvard dataset. After Cox regression analysis 
with the adjustment for age and sex, eight SNPs remained significantly associated with CMSS 
at P ≤ 0.05 in an additive genetic model, including four SNPs (rs10090371, rs62525943, 
rs12674820, and rs7013966) in MMP16, two SNPs (rs788933 and rs788935) in ADAMTS3, one 
SNP (rs10882807) in TLL2, and one SNP (rs3918251) in MMP9 (Table 1).  
 
Independent representative SNPs 
We then performed a stepwise Cox regression analysis of selected clinical variables from 
the MDACC dataset plus the eight validated SNPs to identify independent predictors of CMSS 
from the eight validated SNPs (Table 2). Four SNPs rs10090371, rs788935, rs10882807 and 
rs3918251 remained significant in the final model and thus were selected as independent 
representative SNPs for further analysis. All genotyped and imputed SNPs are shown in the 
regional association plots with an expansion of 250 KB in the flanks of the gene region, in which 
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the selected four independent representative SNPs, as shown on the top of the plots, are 
labeled in purple (Supplementary Figure 2). 
 
Survival analyses of the four independent SNPs and CMSS in MDACC and Harvard 
studies 
We performed survival analysis with different genetic models for each independent SNP. 
As shown in Table 1, we found that under an additive genetic model, MMP16 rs10090371 A, 
ADAMTS3 rs788935 C and TLL2 rs10882807 C variant alleles were associated with an 
increased death risk of CM, with a variant-allele attributed HR of 1.70 (95% CI = 1.19-2.43, P = 
0.003), 1.41 (95% CI = 1.05-1.89, P = 0.023) and 1.63 (95% CI = 1.19-2.22, P = 0.002) in the 
MDACC study and 1.79 (95% CI = 1.15-2.79, P = 0.010), 1.55 (95% CI = 1.03-2.33, P = 0.034) 
and 1.76 (95% CI = 1.18-2.63, P = 0.005) in the Harvard study and 1.73 (95% CI = 1.32-2.29, P 
= 9.68E-05), 1.46 (95% CI = 1.15-1.85, P = 0.002) and 1.68 (95% CI = 1.31-2.14, P = 3.32E-05) 
in a meta-analysis of the two studies. In addition, the MMP9 rs3918251 G allele was associated 
with a decreased death risk of CM, with a variant-allele attributed HR of 0.69 (95% CI = 0.50-
0.95, P = 0.025) in the MDACC study and 0.63 (95% CI = 0.40-1.00, P = 0.050) in the Harvard 
study and 0.67 (95% CI = 0.51-0.87, P = 0.003) in a meta-analysis of the two studies. The 
univariate and multivariate Cox regression analyses with different genotype models 
(codominant/dominant/additive) of each representative SNP are presented in Table 3. 
 
Combined genotype analyses of the four independent representative SNPs   
We combined the risk genotypes of rs10090371 CA+AA, rs788935 TC+CC, rs10882807 
TC+CC and rs3918251 AA into a genetic score to assess the joint effect of the four independent 
SNPs on CMSS. We first combined groups of 0 and 1 risk genotypes into one group, because 
of their small number of subjects, and categorized all other patients into four groups (i.e., 0 to 4 
genetic scores, Table 3). Results suggested a risk-genotype dose-response in the effect on 
This article is protected by copyright. All rights reserved 
 
11 
CMSS associated with the genetic score (Ptrend < 0.001 in both MDACC and Harvard studies) 
after adjustments (Table 3). We further dichotomized the patients into a low-score risk group (0-
2 risk genotypes) and a high-score risk group (3-4 risk genotypes). A similar result was 
observed that the high-score risk group had an increased risk of death with an HR of 3.55 (95% 
CI = 2.30-5.50, P < 0.001) in the MDACC study and an HR of 2.77 (95% CI = 1.56-4.90, P < 
0.001) in the Harvard study, compared with the low-score risk group. Kaplan-Meier curves were 
also provided to illustrate the association between the number of risk genotypes and CMSS 
(Figure 2A-D). 
 
Stratified analyses for the effect of combined risk genotypes on CMSS 
We then conducted stratified analyses to evaluate whether the combined effect of risk 
genotypes as defined by the genetic score on CMSS was modified by clinical characteristics, 
including age, sex, metastasis, Breslow thickness, ulceration and mitotic rate in the MDACC 
dataset and age and sex in the Harvard dataset. In the MDACC dataset, we found that a high-
score risk genotypes was associated with an increased risk of CM death with HR of 2.19 in the 
non-metastasis group, and 6.38 in the regional or distant metastasis group, and heterogeneity 
was observed between these two subgroups (P = 0.018) (Supplementary Table 3). No 
heterogeneity was found in the subgroups of the Harvard dataset. 
 
ROC curve and time-dependent AUC estimators in the MDACC study 
We used the estimates for the ROC curve and the time-dependent AUC in the MDACC 
study to assess the improvement in prediction accuracy when including the four independent 
SNPs in the presence of other host and clinical variables (i.e., age, sex, metastasis, Breslow 
thickness, ulceration and mitotic rate). From the ROC curve, we found that the combination of 
clinical variables and risk genotypes enhanced the prediction effect of five-year CMSS, 
compared with the group of clinical variables only (AUC = 81.4% to 78.6%), and the time-
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dependent AUC curve showed this effect from the beginning to the end of the follow-up time 
(Figure 2E-F). We did not evaluate ROC curve and time-dependent AUC estimators in the 
Harvard dataset, because clinical variables other than age and sex were unavailable.  
 
eQTL analyses 
We further analyzed the associations between the four independent SNPs and levels of 
the corresponding gene mRNA expression (i.e., expression quantitative trait loci analysis, eQTL 
analysis) using the data from the GTEx Portal (http://www.gtexportal.org/home/), which has the 
data for MMP16 rs10090371 in thyroid tissue, its moderate LD SNP rs12674820 in MMP16 (r2 = 
0.44) in adipose (subcutaneous) tissue and TLL2 rs10882807 in skin tissue. As shown in 
Supplementary Figure 3A-C, MMP16 rs10090371 A, MMP16 rs12674820 G and TLL2 
rs10882807 C alleles were associated with an increase in the corresponding gene mRNA 
expression levels with P values of 2.00E-05, 6.50E-10 and 1.30E-07, respectively. Because 
there were no expression data for the other two SNPs (ADAMTS3 rs788935 and MMP9 
rs3918251) in the GTEx Portal, we further explored the potential function for these two SNPs by 
using the ENCODE project data. As shown in Supplementary Figure 3D-E, ADAMTS3 
rs788935 is located at the intron region that shows H3K4Me1 enrichment, and MMP9 
rs3918251 is also located at the intron region that is a DNaseⅠhypersensitive area. 
 
DISCUSSION  
Metzincins are considered key molecules in degradation of the extracellular matrix and 
play an important role in a variety of biological processes and pathological disorders, such as 
asthma, rheumatoid arthritis and cancer [34], including CM. The alterations of the metzincin 
metallopeptidase family genes in CM development and progression have been previously 
reported [18-21].  
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In the present study, we performed survival analysis for genetic variants in 75 metzincin 
metallopeptidase family genes and CMSS using the available MDACC and Harvard GWAS 
datasets. Four independent representative SNPs (MMP16 rs10090371 C>A, ADAMTS3 
rs788935 T>C, TLL2 rs10882807 T>C and MMP9 rs3918251 A>G) were identified as predictors 
of CMSS. Specifically, rs10090371A, rs788935C and rs10882807C alleles were associated with 
a poor CMSS, and the rs3918251G allele was associated with a favorite outcome of CM. When 
we considered these four risk genotypes together, we also found that there was a risk-genotype 
dose-response in the effect on CMSS associated with the genetic score combining the four risk 
genotypes (rs10090371 CA+AA, rs788935 TC+CC, rs10882807 TC+CC and rs3918251 AA). 
These four independent SNPs highlighted the roles of four genes (MMP16, ADAMTS3, TLL2 
and MMP9) in CM patient survival.  
MMP16, located at 8q21.3, encodes an enzyme called matrix metalloproteinase 16, which 
is a family member of matrix metalloproteinases (MMPs). Like the other MMPs, MMP16 is also 
associated with cancer cell proliferation, invasion and metastasis [35]. It is suggested that 
MMP16 contributes to a poor prognosis in gastric cancer by promoting tumor cell proliferation 
and invasion [35]. Other studies have reported that MMP16 was associated with the migration 
and invasion of glioma and pancreatic cancer [36,37]. Therefore, targeting MMP16 may be a 
feasible approach for inhibiting the progression of several cancers. Furthermore, MMP16 has 
been proposed to influence cell-cell adhesion and lymphatic invasion in melanoma [38]. Taken 
together, MMP16 may be considered to act as an oncogene and contribute to poor prognosis in 
multiple cancers, including CM. In the present study, the rs10090371 AA variant genotype was 
associated with an decreased CMSS, compared with the CC genotype, and the AA genotype 
was also associated with an increased MMP16 mRNA expression in thyroid tissue, although we 
did not have the data for skin or cutaneous tissue from the GTEx portal, another SNP 
rs12674820 in moderate LD (r2 = 0.44) with rs10090371 was associated with increased MMP16 
mRNA expression in subcutaneous tissue, which was consistent with the result of rs10090371 
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in thyroid tissue. Therefore, it appears likely that SNPs in this region may influence  gene 
function by mediating mRNA expression levels in multiple tissue types. 
ADAMTS3, located at 4q13.3, encodes an enzyme called ADAM metallopeptidase with 
thrombospondin type 1 motif 3. As one of adamlysins family genes, ADAMTS3 also participates 
in various cellular processes, including extracellular matrix degradation, cleavage of 
proteoglycans, inhibition of angiogenesis, gonadal development and organogenesis [39]. One 
study reported that ADAMTS3 was downregulated in breast cancer [39]. To date, there is no 
report about the role of ADAMTS3 in melanoma. In the present study, we found an association 
between the ADAMTS3 rs788935 and CM prognosis. According to the ENCODE project data 
from UCSC, rs788935 is located at the intron region of ADAMTS3, which demonstrates 
considerable levels of H3K4Me1 enrichment that is accessible to transcription factors to 
enhance transcriptional activity. Therefore, it appears likely that SNPs in this region may 
influence gene expression by mediating the transcriptional activity. 
TLL2, located at 10q24.1, encodes a protein called tolloid-like protein 2, which is an 
astacin-like zinc-dependent metalloprotease and is a subfamily member of the metzincin family. 
In the present study, this is the first report of an association between the TLL2 rs10882807CC 
variant genotype and CM survival, and likely this genotype increases TLL2 mRNA expression in 
a variant allele dose-response manner in skin tissue. Therefore, we propose that TLL2 may 
function as an oncogene to influence the melanoma progression. We acknowledge that 
additional functional studies are needed to validate our findings. 
MMP9, located at 20q13.12, encodes an enzyme called matrix metallopeptidase 9 that 
also belongs to the MMPs family. MMP9 has been reported to be associated with the 
development and progression of many cancers. For example, one study reported that 
upregulating of MMP9 expression promoted hepatocellular carcinoma cell migration and 
invasion [40]. Another study suggested that increased MMP9 expression was associated with 
gastric cancer cell invasion [41]. In addition, MMP9 activity has been reported to be correlated 
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with prognosis of other cancers, including cancers of the lung [42], colorectum [43], esophagus 
[44] and breast [45]. Importantly, transcript levels of MMP9 were also observed to be increased 
in melanoma tumors, compared with that of melanocyte controls [46]. Additionally, it has been 
reported that MMP9 silencing inhibited mouse melanoma cell invasion and migration both in 
vitro and in vivo, suggesting that MMP9 might have promising applications for target therapy of 
CM [47]. Taken together, these data suggest that MMP9 acts as an oncogene contributing to 
poor prognosis across multiple cancers, including CM. In the present study, we found that the 
rs3918251 GG variant genotype was a protective factor for CMSS. According to the ENCODE 
project data from UCSC, rs3918251 is located at the DNaseⅠ hypersensitive area, where has 
lost the condensed structure, exposing the DNA and making it accessible to DNaseⅠand 
transcription factors, plausibly influencing transcriptional activity. However, stronger functional 
evidence is needed to unravel the biological mechanisms underlying the observed association 
with CM survival. 
There are some limitations in the present study. First, the MDACC study included clinical 
variables such as age, sex, primary tumor Breslow thickness, regional/distant metastasis, 
ulceration and mitotic rate for adjustment, but the Harvard study included only age and sex. 
Furthermore, additional potentially important clinical variables were not available for inclusion, 
such as performance status, nutritional status, tumor somatic mutation data, and details 
regarding treatment and response. Second, the study patients by design were all non-Hispanic 
whites, therefore, our findings cannot be generalized to the general populations, and validations 
in other ethnic groups are needed. Third, the GTEx portal and other biological function 
prediction websites are limited in their ability to definitively evaluate the function of the SNPs 
identified. More functional evidence is needed, and potential biological mechanisms should be 
explored by using the accessible melanoma tissues. 
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In conclusion, we evaluated associations between genetic variants of 75 metzincin 
metallopeptidase family genes and CMSS using MDACC and Harvard GWAS datasets. We 
identified MMP16 rs10090371 C>A, ADAMTS3 rs788935 T>C, TLL2 rs10882807 T>C and 
MMP9 rs3918251 A>G as possible predictors for CMSS. Additional population replications from 
other ethnic groups and functional validation from mechanistic studies are needed to further 
validate our results. Once validated, our findings may provide promising prognostic biomarkers 
for personalized management and treatment of CM patients.     
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Figure 1. Research flowchart. SNP, single nucleotide polymorphism; CMSS, cutaneous 
melanoma-specific survival; FPRP, false-positive report probability; ROC, receiver operating 
characteristic; GWAS, genome-wide association study. 
Figure 2. A-D: Kaplan-Meier survival curves for melanoma patients of combined analysis of 
four risk genotypes in MMP16, ADAMTS3, TLL2, and MMP9 in MDACC and Harvard studies. A. 
Combined analysis of risk genotypes (four groups) in MDACC study; B. Combined analysis of 
risk genotypes (two groups) in MDACC study; C. Combined analysis of risk genotypes (four 
groups) in Harvard study; D. Combined analysis of risk genotypes (two groups) in Harvard study. 
E-F:  Receiver operating characteristic (ROC) curve and time-dependent area under the ROC 
curve (AUC) estimation for prediction of melanoma-specific survival using MDACC dataset. E. 
Ten-year melanoma-specific survival rate; F. Time-dependent AUC estimation, based on age, 
sex, Breslow thickness, regional/distant metastasis, ulceration, mitotic rate and the risk 
genotypes of the four genes. 
Supplementary Figure 1. Manhattan plot of 13,850 SNPs of metzincin metallopeptidase family 
genes in the MDACC study. The statistical values across the autosomes for associations 
between 13,850 SNPs and melanoma-specific survival are plotted as −log10 P values. The red 
horizontal line indicates P = 0.05. The eight validated SNPs are marked with red points. 
Supplementary Figure 2. Regional association plots of the four independent SNPs in the 
metzincin metallopeptidase family genes. The left-hand Y-axis shows the -log10 transformation 
of P-value of individual SNPs, which is plotted against the chromosomal base-pair position with 
an extension of 250 KB in flanking region of the genes. The right-hand Y-axis shows the 
recombination rate estimated for European population from HapMap Data Rel 22/phase II. A. 
MMP16 rs10090371; B. ADAMTS3 rs788935; C. TLL2 rs10882807; D. MMP9 rs3918251. 
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Supplementary Figure 3. A-C: Tissue-specific eQTL analyses of the SNPs (rs10090371, 
rs12674820 and rs10882807) and corresponding gene mRNA expression. All the data are from 
oncomine website (https://www.oncomine.org/resource/main.html). A. MMP16 rs10090371 (P = 
2.00E-05); B. MMP16 rs12674820 (P = 6.50E-10); C. TLL2 rs10882807 (P = 1.30E-07) (There 
are no tissue-specific eQTL results about ADAMTS3 rs788935 and MMP9 rs3918251). D-E: 
Annotations of rs788935 and rs3918251 in the metzincin metallopeptidase family genes from 
ENCODE project data on the University of California Santa Cruz (UCSC, 
http://genome.ucsc.edu/). D. ADAMTS3 rs788935; E. MMP9 rs3918251. 
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Table 1. Meta-analysis of eight validated SNPs using two published melanoma GWAS datasets 
SNP Allelea Gene 
MDACC (n=858) Harvard (n=409) Meta-analysis Prior probabilityf 
EAF HR (95%CI)b Pb EAF HR (95%CI)c Pc Phet
d I2 HR (95%CI)e Pe 0.25 0.1 0.01 0.001 0.0001 
rs10090371 C/A MMP16 0.20 1.70 (1.19-2.43) 0.003 0.18 1.79 (1.15-2.79) 0.010 0.86 0 1.73 (1.32-2.29) 9.68E-05 0.012 0.036 0.291 0.805 0.976 
rs62525943 C/T MMP16 0.20 1.70 (1.19-2.43) 0.003 0.18 1.74 (1.11-2.74) 0.016 0.94 0 1.72 (1.30-2.27) 1.52E-04 0.012 0.036 0.291 0.805 0.976 
rs12674820 C/G MMP16 0.31 1.47 (1.07-2.03) 0.017 0.28 1.81 (1.19-2.74) 0.005 0.44 0 1.59 (1.23-2.05) 3.42E-04 0.051 0.138 0.638 0.947 0.994 
rs7013966 C/T MMP16 0.43 1.42 (1.04-1.92) 0.027 0.40 1.53 (1.01-2.31) 0.045 0.78 0 1.46 (1.14-1.87) 0.003 0.076 0.198 0.731 0.965 0.996 
rs788933 G/A ADAMTS3 0.42 1.41 (1.05-1.89) 0.023 0.42 1.55 (1.03-2.33) 0.034 0.71 0 1.46 (1.15-1.85) 0.002 0.065 0.173 0.696 0.959 0.996 
rs788935 T/C ADAMTS3 0.42 1.41 (1.05-1.89) 0.023 0.42 1.55 (1.03-2.33) 0.034 0.71 0 1.46 (1.15-1.85) 0.002 0.065 0.173 0.696 0.959 0.996 
rs10882807 T/C TLL2 0.45 1.63 (1.19-2.22) 0.002 0.48 1.76 (1.18-2.63) 0.005 0.77 0 1.68 (1.31-2.14) 3.32E-05 0.007 0.020 0.184 0.694 0.958 









SNP, single nucleotide polymorphisms; GWAS, genome-wide association study; MDACC, The University of Texas MD Anderson cancer center; EAF, effect allele frequency; HR, 
hazards ratio; CI, confidence interval; 
aReference allele/effect allele;  
bAdjusted for age, sex, Breslow thickness, distant/regional metastasis, ulceration  and mitotic rate in Cox models of SNPs and melanoma-specific survival in MDACC study and all 
the tests of the proportional hazards assumption for the validated SNPs were not significant (P > 0.05);  
cAdjusted for age and sex in Harvard study; 
dPhet: P value for heterogeneity by Cochrane’s Q test; 
eMeta-analysis in the fix-effect model; 
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Table 2. Independent predictors of CMSS as obtained from the stepwise Cox regression analysis of selected variables from the 
MDACC dataset  
Parametera Categoryb Frequency HR (95% CI) P 
Age ≤50/>50 371/487 1.02 (1.01-1.04) 0.010 
sex Female/Male 362/496 1.29 (0.80-2.07) 0.292 
Regional/distant metastasis No/Yes 709/149 4.43 (2.87-6.84) <0.001 
Breslow thickness(mm) ≤1/>1 347/511 1.21 (1.15-1.28) <0.001 
Ulceration No/Yes 681/155 2.82 (1.83-4.34) <0.001 
Mitotic rate (mm2) ≤1/>1 275/583 2.40 (1.17-4.94) 0.017 
rs10090371 C>A CC/CA/AA 546/287/25 1.80 (1.26-2.57) 0.001 
rs788935 T>C TT/TC/CC 277/434/147 1.53 (1.13-2.06) 0.006 
rs10882807 T>C TT/TC/CC 266/418/174 1.63 (1.20-2.22) 0.002 






CMSS, cutaneous melanoma-specific survival; MDACC, The University of Texas MD Anderson cancer Center; HR, hazards ratio; CI, confidence interval; 
aStepwise analysis included age, sex, regional/distant metastasis, Breslow thickness, ulceration, mitotic rate and eight SNPs in four genes (rs10090371, 
rs62525943, rs12674820 and rs7013966 in MMP16; rs788933 and rs788935 in ADAMTS3; rs10882807 in TLL2; and rs3918251 in MMP9); 
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Table 3. Associations between four independent SNPs in the metzincin metallopeptidase family genes and CMSS of patients in the 
MDACC study and Harvard study 
Genotype 
MDACC   Harvard 
Frequency Univariate analysis Multivariate analysisa 
 
Frequency Univariate analysis Multivariate analysisb 
All Death (%) HR (95%CI) P HR (95%CI) P   All Death (%) HR (95%CI) P HR (95%CI) P 
MMP16 rs10090371 C>A 








CA 287 39 (13.6) 1.49 (0.98-2.26) 0.062 1.62 (1.05-2.49) 0.028 
 
117 18 (15.4) 1.69 (0.93-3.09) 0.086 1.77 (0.97-3.24) 0.062 
AA 25 5 (20.0) 2.13 (0.85-5.33) 0.108 3.30 (1.29-8.43) 0.013 
 
15 4 (26.7) 2.89 (1.01-8.28) 0.048 3.26 (1.13-9.38) 0.029 
CA+AA 312 44 (14.1) 1.54 (1.03-2.30) 0.036 1.72 (1.13-2.61) 0.011 
 
132 22 (16.7) 1.83 (1.04-3.23) 0.037 1.93 (1.09-3.41) 0.023 
Trend 








ADAMTS3 rs788935 T>C 








TC 434 55 (12.7) 1.65 (1.01-2.71) 0.046 1.99 (1.19-3.31) 0.008 
 
202 24 (11.9) 1.46 (0.71-2.98) 0.301 1.48 (0.72-3.02) 0.285 
CC 147 18 (12.2) 1.64 (0.88-3.05) 0.121 1.91 (1.00-3.66) 0.052 
 
72 13 (18.1) 2.33 (1.04-5.20) 0.039 2.40 (1.07-5.37) 0.033 
TC+CC 581 73 (12.6) 1.65 (1.02-2.66) 0.040 1.97 (1.20-3.22) 0.007 
 
274 37 (13.5) 1.68 (0.86-3.29) 0.132 1.71 (0.87-3.35) 0.120 
Trend 








TLL2 rs10882807 T>C 








TC 418 53 (12.7) 1.51 (0.93-2.46) 0.099 2.07 (1.22-3.53) 0.007 
 
184 16 (8.7) 1.05 (0.48-2.32) 0.903 1.03 (0.47-2.28) 0.940 
CC 174 19 (10.9) 1.30 (0.71-2.39) 0.394 2.62 (1.36-5.06) 0.004 
 
105 22 (21.0) 2.57 (1.22-5.43) 0.013 2.65 (1.25-5.60) 0.011 
TC+CC 592 72 (12.2) 1.45 (0.91-2.32) 0.122 2.19 (1.31-3.66) 0.003 
 
289 38 (13.2) 1.60 (0.80-3.21) 0.188 1.60 (0.80-3.21) 0.188 
Trend 
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AG 394 36 (9.1) 0.61 (0.40-0.94) 0.027 0.52 (0.33-0.82) 0.005 
 
192 14 (7.3) 0.39 (0.21-0.75) 0.004 0.42 (0.22-0.79) 0.008 
GG 122 11 (9.0) 0.67 (0.35-1.29) 0.226 0.64 (0.33-1.25) 0.191 
 
50 6 (12.0) 0.66 (0.27-1.58) 0.348 0.64 (0.27-1.56) 0.327 
AG+GG 516 47 (9.1) 0.63 (0.42-0.93) 0.022 0.55 (0.36-0.83) 0.004 
 
242 20 (8.3) 0.45 (0.25-0.79) 0.006 0.47 (0.26-0.83) 0.010 
Trend 








Number of risk genotypesc 










 1 187 13 (7.0) 
 
94 4 (4.3) 
2 337 29 (8.6) 1.26 (0.68-2.36) 0.461 1.93 (0.96-3.89) 0.066 
 
171 17 (9.9) 2.70 (0.91-8.02) 0.074 2.86 (0.96-8.50) 0.059 
3 238 38 (16.0) 2.50 (1.38-4.54) 0.003 5.18 (2.59-10.36) <0.001 
 
110 21 (19.1) 5.45 (1.87-15.87) 0.002 5.50 (1.89-16.03) 0.002 
4 63 13 (20.6) 3.27 (1.55-6.87) 0.002 6.84 (2.96-15.79) <0.001 
 
24 6 (25.0) 7.51 (2.12-26.62) 0.002 7.53 (2.11-26.84) 0.002 
Trend 























SNP, single nucleotide polymorphisms; CMSS, cutaneous melanoma-specific survival; GWAS, genome-wide association study; MDACC, The University of Texas MD 
Anderson cancer center; HR, hazards ratio; CI, confidence interval; 
aAdjusted for age, sex, Breslow thickness, distant/regional metastasis, ulceration  and mitotic rate in Cox models of SNPs and CMSS in MDACC study;  
bAdjusted for age and sex in Harvard study;          
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Figure 2 
 
 
